🔗 Share this article

Given that the US proceeds with historic adjustments to its immunization guidelines, one figure has surfaced in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who first made her name by casting doubt on coronavirus shots during the global health crisis and has focused upon potential fatalities following COVID-19 vaccination in her short time at the FDA.

Scheduled Changes to Pediatric Immunization Program

Public health authorities planned to announce sweeping revisions to the childhood vaccination calendar in December, synchronizing the US with Denmark’s immunization schedule, sources say – a significant shift that would put the US out of step with a large portion of the international standard with no evidence for benefit. The planned update has been delayed until the coming year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to address the audience at the event. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to lead the office this calendar year.

A Shift at the Agency

Høeg's temporary position may indicate a tighter collaboration between the drug and vaccine centers as Høeg and Prasad strengthen their influence at the FDA – and it points to a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Høeg has often pushed for ending specific pediatric vaccine recommendations in the US in order to be more in line with Denmark, a country with nationalized medicine and a citizenry roughly the population of the state of Wisconsin.

So far statements, she has persisted in emphasizing on immunizations – usually the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Questions Over Expertise

Dr. Høeg has no apparent background in medication creation, regulation or administrative roles, which has been standard for previous heads of the CBER. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since spring.

“She appears not to have the requisite experience” for leading the CDER, said Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in running a major agency. She is not an expert in industry regulation.”

Past commissioners of CBER would “be deeply familiar with legal statutes and the science of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she has not acquired the kind of background that prior appointees who ran the center have had.”

This division has an vast workload at the agency, she emphasized.

“Many people just zeroes in on the novel medication approvals, but the off-patent medication office approves a multitude of generic medications. There’s a biologic copycat branch, over-the-counter program and other areas, and all of those have to be looked after,” Woodcock noted. “The area you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial leadership aspect to the job, which supervises more than 5,000 personnel. “It is a huge leadership role, if you do it right,” she said.

Official Statement and Contentious Programs

When asked about concerns about Dr. Høeg's fitness for the role and whether this selection signifies greater collaboration among regulatory chiefs on immunizations, a representative said that the “questions stem from inaccurate assumptions”.

“Her resume aligns with the responsibilities of her role,” the official said, noting the months Høeg spent advising the agency head on “drug safety and approval science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg takes over the commissioner’s controversial fast-track approval initiative, a disputed one-day medication authorization process that apparently concerned her former heads. “How are these drugs being selected for this expedited pathway? Who takes the choices?” Dr. Howard said. “There’s a lot of confidentiality happening at the FDA right now.”

Broadly speaking, he remarked, “the FDA seems to be moving towards less stringent regulations of all drugs, with the exception of vaccines.”

Public History on Vaccines

Concerning vaccines, Høeg has a more documented, if troubling, history, critics observe. She authored a analysis using unconfirmed crowd-sourced reports to determine the incidence of heart inflammation following COVID-19 immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccinations are pose a greater threat than they are.

Among her “policy goals” for the incoming federal leadership encompassed revising guidelines for recently developed shots and ending “non-essential” immunizations, she said following the vote on a online show. At the FDA, Dr. Høeg has reportedly proposed preventing teenage boys from getting COVID-19 vaccinations.

“She is an thorough true believer who commences with her preconceived notions and reverse-engineers to accommodate the data in a highly disingenuous, dishonest way,” Howard said.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow skeptics, {like|